Most clinical isolates of Staphylococcus aureus produce microcapsules (uronic acid-containing extracellular polysaccharides) that are detectable by serologic methods but are not visible by negative staining. Among the 11 reported serotypes, capsule types 5 and 8 comprise -75% of all isolates. Transposon mutagenesis was performed on S. aureus to create mutants altered in capsule expression. Tn918 was introduced into the capsule type 5 strain Reynolds by filter mating, and a capsule-deficient transconjugate, JL236, was isolated. The wild-type strain was transformed with JL236 chromosomal DNA to confirm that transfer of the appropriatesize chromosomal fragment containing Tn918 generated a capsule-deficient transformant. Strain Reynolds was mutagenized with ethyl methanesulfonate to obtain a capsule-negative mutant (strain JL240). Capsular phenotypes were determined by colony immunoblots, antibody adsorption experiments, and transmission electron microscopy. The virulences of the parental and mutant strains in mice were compared. The 50% lethal doses for strains Reynolds, JL236, and JL240 were similar (108.59, 108.98, and 108.93 CFU, respectively).
Microorganisms that cause invasive disease often produce extracellular capsular polysaccharides. Capsules from a number of bacterial pathogens have been shown to enhance virulence and to elicit protective antibodies (28) . Although capsule production by staphylococci was first recognized in 1930 by Gilbert (9) , only recently has the prevalence of encapsulation among Staphylococcus aureus strains been appreciated. This is due largely to the efforts of Karakawa and Vann, who serologically and biochemically distinguished 11 capsular types among clinical isolates (15, 29) . Recent studies by a number of investigators have focused on the chemical and biologic properties of the S. aureus capsule and on the prevalence of capsule expression among staphylococcal isolates from many sources (1-3, 12, 14-16, 26, 29) . Encapsulated S. aureus strains produce extracellular polysaccharides that are usually composed of aminouronic acid sugars and fucosamine (15) . Highly encapsulated, mucoid strains belong to serotype 1 or 2 and are rarely isolated (2, 29) . Most clinical isolates are microencapsulated, i.e., they form nonmucoid colonies and their capsules are not made apparent by negative stains such as India ink (2, 15) . Type 5 and 8 strains predominate, constituting -22 and -53%, respectively, of isolates examined (1, 2, 12, 15, 26) .
We previously examined the biologic properties associated with type 1 capsule expression by using TnS51 insertional mutagenesis of a highly encapsulated, mucoid strain of S. aureus (16) . The highly encapsulated parent strain was more virulent for mice than either a microencapsulated type 1 mutant or a nonencapsulated mutant. Only the highly encapsulated strain showed enhanced lethality for mice and required specific capsular antibodies for in vitro complement-mediated opsonophagocytic killing. The microencapsulated mutant was not more virulent in mice than the nonencapsulated mutant strain, and neither mutant required capsular antibodies for in vitro complement-mediated opsonophagocytosis. These studies not only established the importance of the type 1 capsule in staphylococcal virulence but also suggested that microencapsulated strains of S. aureus do not share the biologic properties (enhanced virulence and resistance to phagocytosis) associated with highly encapsulated S. aureus strains.
Because type 5 strains represent a large proportion of clinical isolates of S. aureus, we wanted to determine whether the microcapsules produced by these strains promoted staphylococcal virulence. In this report, we describe in vitro mutagenesis experiments to alter capsule expression and in vivo studies to evaluate the virulence of the strains in mice. Our results indicate that microencapsulated type 5 strains of S. aureus are not more virulent for mice than capsule-negative or capsule-deficient mutants.
MATERIALS AND METHODS
Bacteria and antibodies. The bacterial strains used in this study were maintained in skim milk at -70°C and are listed in Table 1 (4) containing tetracycline (1 ,ug/ml), transferred to a culture tube, and incubated at 37°C with shaking for 90 min. Transformants were selected on TSA plates containing tetracycline (5 pLg/ml).
Southern blot hybridizations. To determine the number of transposon insertions in the mutant strains, we isolated chromosomal DNA from wild-type and mutant S. aureus strains. Preparation of bacterial DNA, nick translations, and hybridizations were performed as previously described (16) . Chromosomal DNA was digested with restriction enzymes (New England BioLabs, Beverly, Mass.) under conditions suggested by the manufacturer. Chromosomal digests were hybridized to 32P-labeled pAM120, a 21.2-kb Escherichia coli plasmid that carries Tn916 (8) . The sequence of Tn916 is closely related to that of Tn918, and the two elements cross-hybridize efficiently (5).
Phenotypic characterization. To exclude the possibility that factors other than capsule expression might be altered by mutagenesis, the S. aureus strains were phenotypically characterized as described previously (16) . Immunodiffusion was used to detect production of enterotoxin B by organisms cultivated by the membrane-over-agar method (11) . Production of alpha-toxin was evaluated by measuring zones of hemolysis around colonies grown on TSA plates containing 5% defibrinated rabbit blood. Coagulase in S. aureus culture supernatants was quantitated as described by Phonimdaeng et al. (25) . Cell wall protein A content was measured by bacterial agglutination with immunoglobulin-coated sheep erythrocytes (23) . Lipase and protease production were evaluated on egg yolk agar plates (BBL).
Antibody adsorption studies. To confirm the capsular phenotype of the mutants, we tested their ability to adsorb capsular antibodies from rabbit immune serum. Bacteria grown overnight on TSA plates at 37°C were suspended and washed in PBS. Pellets adjusted to contain the same number of CFU were heat killed for 1 h at 70°C before they were incubated with 1 ml of 0.01 M phosphate buffer-0.1% trypsin, pH 8.0, for 1 h at 37°C to remove protein A. After three washes in PBS, dilutions of each bacterial suspension were incubated with rabbit serum at 4°C overnight. Sera were clarified by centrifugation, filter sterilized, and added to wells of microtiter plates coated with CP5 (1 to 2 ,ug/ml) that was coupled to poly-L-lysine by the cyanuric chloride method (10 (17) .
Electron microscopy. F(ab')2 fragments of immunoglobulin G (IgG) were prepared from rabbit serum raised to strain Reynolds by using an F(ab')2 preparation kit (Pierce Chemical Co., Rockford, Ill.). Following pepsin digestion, the sample was passed over a protein A column (to remove undigested IgG and Fc fragments) and dialyzed against PBS. Analysis by sodium dodecyl sulfate-polyacrylamide gel electrophoresis was used to verify that F(ab')2 fragments were recovered by this procedure.
Overnight cultures of S. aureus Reynolds, JL236, and JL240 were fixed with 1% glutaraldehyde-0. 1% CaCl2 for 30 min at 4°C. The bacteria were recovered by centrifugation, washed, and incubated for 2 h at ambient temperature with F(ab')2 fragments of IgG (2.4 mg of protein) prepared from serum raised to strain Reynolds. The cells were washed five times with PBS and then incubated overnight at 4°C with ferritin-labeled F(ab')2 fragments of goat anti-rabbit IgG, generously provided by Shilu Xu, Boston, Mass. Samples were washed again and processed further for electron microscopy as previously described (16 [17] [18] [19] [20] (22) . This pattern of serologic reactivity was identical to that observed with the original Tn918 mutant, JL236. Southern blots were performed on DNA digests of JL236 and of six of the eight transformants (Fig. 2) similar doubling times and produced comparable levels of alpha and beta hemolysins, coagulase, and protein A. Metabolic enzymes and carbohydrate utilization profiles of the parent and the mutant strains were identical.
Electron microscopy. We used transmission electron microscopy to verify the capsular phenotypes of the wild-type and mutant S. aureus strains. Strain Reynolds elaborated a microcapsule that was visualized by using F(ab')2 fragments of capsular antibodies and ferritin-conjugated F(ab')2 secondary antibodies (Fig. 3) . JL236 produced a scant amount of the type 5 capsule, whereas JL240 appeared nonencapsulated.
Antibody adsorption studies. To confirm the capsular phenotypes of the mutant strains, we tested their ability to adsorb capsular antibodies from polyclonal serum. Antibody binding to CP5-coated ELISA plates was not diminished by adsorption of rabbit serum raised to strain Reynolds with more than l0O CFU of a nontypeable strain or of the heterologous type 8 strain Becker (Fig. 4) . In contrast, sera adsorbed with 106 CFU of strain Reynolds (Cm) showed less than 50% binding. Suspensions of 2.5 x 108 CFU of the capsule-deficient strain JL236 adsorbed -67% of the capsular antibodies, which is consistent with the scant amounts of CP5 visualized on this strain by transmission electron microscopy. After adsorption with the EMS mutant JL240 at 2.5 x 109 CFU/ml, the type S rabbit sera exhibited -50% binding to purified CP5.
Mouse lethality. To determine the influence of the microcapsule on lethality, CD-i mice were injected i.p. with either the wild-type or the mutant strains. LD50s for strains Reynolds (Cmr), JL236 (Tn918 capsule-deficient mutant), and JL240 (EMS capsule-negative mutant) were similar (108-59, lo8.98, and 108-93 CFU, respectively).
Mouse bacteremia. To determine whether the parental and mutant strains differed in invasiveness, bacteria were injected i.p. into groups of 20 CD-i mice. Quantitative blood cultures were made for 10 mice at 3 h after challenge with each strain and for another 10 mice at 24 h after challenge with each strain. As shown in Table 2 , significant differences between the bacteremia levels of mice challenged with the microencapsulated strain of S. aureus and those of mice challenged with the mutant strains of S. aureus were not seen. (29) . The virulent for mice that an isogenic, nonencapsulated strain Lar types 5 and 8 has been observed in (16 (19, 20, 31) . Adherence studies comparing microencapsulated and nonencapsulated S. aureus strains have not yet been reported.
